| Identification | Back Directory | [Name]
Benzeneacetamide, 4-(ethylsulfonyl)-N-[2'-fluoro-4'-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl][1,1'-biphenyl]-4-yl]- | [CAS]
2349368-16-5 | [Synonyms]
XY101
Benzeneacetamide, 4-(ethylsulfonyl)-N-[2'-fluoro-4'-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl][1,1'-biphenyl]-4-yl]- | [Molecular Formula]
C25H20F7NO4S | [MDL Number]
MFCD32067982 | [MOL File]
2349368-16-5.mol | [Molecular Weight]
563.48 |
| Chemical Properties | Back Directory | [Boiling point ]
682.4±55.0 °C(Predicted) | [density ]
1.439±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: 250 mg/mL (443.67 mM) | [form ]
Solid | [pka]
8.87±0.19(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Description]
XY101 is a Potent, Selective, and Orally Bioavailable RORγ Inverse Agonist for Treatment of Castration-Resistant Prostate Cancer with IC50 = 30nM. XY101 potently inhibited cell growth, colony formation, and the expression of AR, AR-V7, and PSA. XY101 also exhibited good metabolic stability and a pharmacokinetic profile with oral bioavailability of 59% and a half-life of 7.3 h. Notably, XY101 demonstrated promising therapeutic effects with significant tumor growth inhibition in a prostate cancer xenograft model inmice. |
|
|